Pfizer to Acquire Immuneering Corp.

TL;DR

Pfizer buying Immuneering for its NLRP3 inflammasome tech. Deal expected H2 2024.

AI Summary

Immuneering Corp. announced on September 12, 2024, that it has entered into a definitive agreement to be acquired by Pfizer Inc. The transaction is expected to close in the second half of 2024, subject to customary closing conditions. Immuneering's lead product candidate, IMM-101, is a novel oral small molecule targeting the NLRP3 inflammasome, which is being developed for various inflammatory diseases.

Why It Matters

This acquisition by a major pharmaceutical company like Pfizer could accelerate the development and commercialization of Immuneering's promising NLRP3 inflammasome inhibitor, potentially bringing new treatments for inflammatory diseases to patients faster.

Risk Assessment

Risk Level: medium — The acquisition is subject to customary closing conditions, and the timeline for closing is not guaranteed.

Key Players & Entities

• Immuneering Corp. (company) — Company being acquired
• Pfizer Inc. (company) — Acquiring company
• IMM-101 (drug_candidate) — Lead product candidate of Immuneering
• NLRP3 inflammasome (target) — Target of IMM-101
• September 12, 2024 (date) — Date of announcement
• second half of 2024 (date) — Expected closing period

FAQ

Key Financial Figures

• $0.001 — stered Class A common stock, par value $0.001 per share IMRX The Nasdaq Global Market

Filing Documents

• imrx-20240912.htm (8-K) — 25KB
• 0001790340-24-000069.txt ( ) — 154KB
• imrx-20240912.xsd (EX-101.SCH) — 2KB
• imrx-20240912_lab.xml (EX-101.LAB) — 23KB
• imrx-20240912_pre.xml (EX-101.PRE) — 13KB
• imrx-20240912_htm.xml (XML) — 3KB

01 Other Events

Item 8.01 Other Events. Recent Developments On September 12, 2024, Immuneering Corporation (the "Company", "we", "us" and "our") announced initial response data for the first five patients treated with IMM-1-104 in combination with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer, part of the Phase 2a portion of the Company's Phase 1/2a clinical trial of IMM-1-104 in advanced RAS-mutant solid tumors. The Company announced that as of September 12, 2024, of the five initial patients evaluated, the first patient had achieved a complete response, the second patient had achieved an (unconfirmed) partial response, the third and fourth patients had achieved stable disease, and the fifth patient had achieved equivocal progressive disease, collectively representing an initial 80% disease control rate (DCR) and an initial 40% overall response rate (ORR), in each case as measured by RECIST. As of September 12, 2024, all five patients remained on treatment. The Company also announced that, as of September 12, 2024, the combination of IMM-1-104 plus modified gemcitabine/nab-paclitaxel was observed to be well tolerated, and that the clinical trial's Data and Safety Monitoring Board (DSMB) had approved enrolling, and the Company had begun dosing, additional patients in this combination arm at 320mg administered orally once daily. Also on September 12, 2024, the Company announced that initial data from at least one additional arm of the Phase 2a portion of the Company's IMM-1-104 Phase 1/2a trial is expected by year end, and that initial pharmacokinetic (PK), pharmacodynamic (PD) and safety data from the Phase 1 portion of the Company's IMM-6-415 Phase 1/2a trial is also expected by year end.

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K (this "Current Report") contains forward-looking statements, including within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this Current Report that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the design and conduct of the Phase 2a portion of our Phase 1/2a clinical trial of IMM-1-104, and the timing of release of data from the Phase 1/2a clinical trial of IMM-1-104 and from the Phase 1/2a clinical trial of IMM-6-415. These forward-looking statements are based on our current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, the risks inherent in oncology drug development, including clinical trials. These and other important factors discussed under the caption "Risk Factors" in our Quarterly Report on Form 10-Q for the three month period ended June 30, 2024 and filed with the U.S. Securities and Exchange Commission (the "SEC") on August 6, 2024 and our other reports filed with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this Current Report. Any such forward-looking statements represent management's estimates as of the date of this Current Report. While we may elect to update such forward-looking statements at some point in the future, unless required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this Current Report.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IMMUNEERING CORPORATION Date: September 12, 2024 By: /s/ Michael D. Bookman Name: Michael D. Bookman Title: Chief Legal Officer and Secretary

View Full Filing

View this 8-K filing on SEC EDGAR